AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer
Go back to AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer| AngioDynamics, Inc. (NASDAQ: ANGO) | Delayed: 15.42 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.42 | 52 Week High | $17.64 | |||
| Open | $15.42 | 52 Week Low | $9.71 | |||
| Day High | $15.42 | P/E | N/A | |||
| Day Low | $15.42 | EPS | $-0.07 | |||
| Volume | 21 | |||||
